Porphyrins as Theranostic Agents from Prehistoric to Modern Times

Theranostics

Volumn 2, Issue 9, 2012, Pages 905-915

  Zhang, Yumiao ^a   Lovell, Jonathan F ^a,b  

^a State University of New York ^*  (United States)

^b The State University of New York   (United States)

Author keywords

Porphyrins; Theranostics

Indexed keywords

AMINOLEVULINIC ACID; DEOXYHEMOGLOBIN; DIAGNOSTIC AGENT; FERRIC ION; FERROUS ION; HEME; HEMOGLOBIN; NANOCARRIER; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYRIN; PROTOPORPHYRIN; VERTEPORFIN;

ACNE; ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BOLD SIGNAL; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGING; MODERN TIMES; NEAR INFRARED SPECTROSCOPY; NONHUMAN; OXYGEN TRANSPORT; PHOTOACOUSTIC TOMOGRAPHY; PHOTOACOUSTICS; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTHERAPY; PREHISTORIC PERIOD; RADIOLYSIS; REVIEW; VENOUS BLOOD; VISUAL IMPAIRMENT; WHOLE BODY IMAGING;

EID: 84872415597     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4908     Document Type: Review

References (151)

1. Meinschein WG, Barghoorn ES, Schopf JW. Biological remnants in a precambrian sediment. Science 1964;145:262-3.
2. Hodgson GW, Peterson E, Kvenvold KA, Bunnenbe E, Halpern B, Pon-nampe C. Search for prophyrins in lunar dust. Science 1970;167:763-5.
3. Barghoorn ES. The oldest fossils. Sci Amer 1971;224:30-42.
4. Canham GWR. Porphyrins and evolutions. Canadian Chemical Education 1972;8:5-6.
5. Zuckerkandl E. The evolution of hemoglobin. Sci Amer 1965;212:110-8.
6. Fermi G, Perutz MF, Shaanan B, Fourme R. The crystal structure of human deoxyhaemoglobin at 1.74 A resolution. J Mol Biol 1984;175:159-74.
7. Schweitzer, MH, Wittmeyer, JL, Horner, JR, Toporski, JK. Soft-tissue vessels and cellular preservation in tyrannosaurus rex. Science 2005;307:1952-5.
8. Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Delivery Rev 2008;60:286-95.
9. Beutler E, Lichtman MA, Coller B.S., Kipps T.J. Examination of the blood. In: Williams' Hematology; 5th ed. New York: McGraw-Hill, Inc. 1995.
10. Hunefeld, F. L. Die chemismus in der thierischen organization. Brock-haus: Leipzig, 1840.
11. Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North ACT. Structure of hemoglobin: A three-dimensional fourier synthesis at 5.5-Å. resolution, obtained by X-ray analysis. Nature 1960;185:416-22.
12. Birren F. Color psychology and color therapy; a factual study of the influence of color on human life. New Hyde Park, NY: University Books, 1961.
13. Birren, Faber. Color & human response: aspects of light and color bear-ing on the reactions of living things and the welfare of human beings. New York: Van Nostrand Reinhold Co., 1978.
14. Kelkar SS, Reineke TM. Theranostics: Combining Imaging and Therapy. Bioconjugate Chem 2011;22:1879-903.
15. Vannotti A. Porphyrins: their biological and chemical importance. Lon-don: Hilger & Watts, 1954.
16. Purcell EM, Torrey HC, Pound RV. Resonance absorption by nuclear magnetic moments in a solid. Phys Rev 1946;69:37-8.
17. Buxton RB. Introduction to Functional Magnetic Resonance Imaging: Principles and Techniques; 1st ed. Cambridge, UK: Cambridge Univer-sity Press, 2002.
18. Belliveau J, Kennedy D, Mckinstry R, Buchbinder B, Weisskoff R, Cohen M, Vevea J, Brady T, Rosen B. Functional mapping of the human visu-al-cortex by magnetic resonance imaging. Science 1991;254:716-9.
19. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A 1992;89:5675-9.
20. Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugur-bil K. Intrinsic signal changes accompanying sensory stimulation: func-tional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 1992;89:5951-5.
21. Ogawa S, Lee T-M, Nayak AS, Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn Reson Med 1990;14:68-78.
22. Bick AS, Goelman G, Frost R. Hebrew brain vs. English brain: language modulates the way it is processed. J Cognitive Neurosci 2010;23:2280-90.
23. Kim C, Favazza C, Wang LV. In vivo photoacoustic tomography of chemicals: high-resolution functional and molecular optical imaging at new depths. Chem Rev 2010;110:2756-82.
24. Xu M, Wang LV. Photoacoustic imaging in biomedicine. Rev Sci Instrum 2006;77:041101.
25. Wang LV. Prospects of photoacoustic tomography. Med Phys 2008;35:5758-67.
26. Wang X, Pang Y, Ku G, Xie X, Stoica G, Wang LV. Noninvasive la-ser-induced photoacoustic tomography for structural and functional in vivo imaging of the brain. Nature Biotechnology 2003;21:803-6.
27. Ermilov SA, Khamapirad T, Conjusteau A, Leonard MH, Lacewell R, Mehta K, Miller T, Oraevsky AA. Laser optoacoustic imaging system for detection of breast cancer. J Biomed Opt 2009;14:024007.
28. Zhang HF, Maslov K, Stoica G, Wang LV. Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging. Nature Biotechnology 2006;24:848-51.
29. Li C, Wang LV. Photoacoustic tomography and sensing in biomedicine. Phys Med Biol 2009;54:R59-R97.
30. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
31. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Pho-tobiol Sci 2002;1:1-21.
32. Kessel D. Delivery of photosensitizing agents. Adv Drug Deliv Rev 2004;56:7-8.
33. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, et al. Photodynamic therapy of cancer: An update. CA-Cancer J Clin 2011;61:250-81.
34. O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in pho-todynamic therapy. Photochem Photobiol 2009;85:1053-74.
35. Brown SB, Brown EA, Walker I. The present and future role of photo-dynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508.
36. Pandey RK, Goswami LN, Chen Y, Gryshuk A, Missert JR, Oseroff A, Dougherty TJ. Nature: A rich source for developing multifunctional agents. Tumor-imaging and photodynamic therapy. Laser Surg Med 2006;38:445-67.
37. Kadish KM, Smith KM, Guilard R. The porphyrin handbook. San Diego: Academic Press, 2000.
38. Lovell JF, Liu TWB, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev 2010;110:2839-57.
39. Moan J. On the diffusion length of singlet oxygen in cells and tissues. J Photochem Photobiol B 1990;6:343-7.
40. Soncin M, Busetti A, Fusi F, Jori G, Rodgers MAJ. Irradiation of amelanotic melanoma cells with 532 nm high peak power pulsed laser radiation in the presence of the photothermal sensitizer Cu(II)-hematoporphyrin: a new approach to cell photoinactivation. Pho-tochem Photobiol 1999;69:708-12.
41. Busetti A, Soncin M, Reddi E, Rodgers MAJ, Kenney ME, Jori G. Photo-thermal sensitization of amelanotic melanoma cells by Ni(II)-octabutoxy-naphthalocyanine. J Photochem Photobiol B 1999;53:103-9.
42. Camerin M, Rello S, Villanueva A, Ping X, Kenney ME, Rodgers MAJ, Jori G. Photothermal sensitisation as a novel therapeutic approach for tumours: Studies at the cellular and animal level. Eur J Cancer 2005;41:1203-12.
43. Camerin M, Rodgers MAJ, Kenney ME, Jori G. Photothermal sensitisa-tion: evidence for the lack of oxygen effect on the photosensitising activ-ity. Photochem Photobiol Sci 2005;4:251-3.
44. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, Chan WCW, Cao W, Wang LV, Zheng G. Porphysome nanovesicles generated by por-phyrin bilayers for use as multimodal biophotonic contrast agents. Na-ture Materials 2011;10:324-32.
45. Lal S, Clare SE, Halas NJ. Nanoshell-enabled photothermal cancer ther-apy: impending clinical impact. Acc Chem Res 2008;41:1842-51.
46. Chen WR, Adams RL, Bartels KE, Nordquist RE. Chromo-phore-enhanced in vivo tumor cell destruction using an 808-nm diode laser. Cancer Lett 1995;94:125-31.
47. Isak SJ, Eyring EM, Spikes JD, Meekins PA. Direct blue dye solutions: photo properties. J Photochem Photobiol A 2000;134:77-85.
48. Mazzaglia A, Trapani M, Micali N, Scolaro LM, Parisi T, Sciortino MT. Investigation of amphiphilic cyclodextrins encapsulating gold colloids and porphyrins for combined photodynamic and photothermal therapy on tumor HeLa cells. J Biotechnol 2010;150:S192-S192.
49. Tappeiner HV, Jesionek A. Therapeutische versuche mit fluoresci-erenden stoffen. Munchener Medizinische Wochenschrift 1903;47:2042-4.
50. Jesionek A, Tappeiner HV. Zur behandlung der hautcarcinome mit fluorescierenden stoffen. Archiv fur klinische Medizin 1905;82:223.
51. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anti-cancer Res 2003;23:3591-600.
52. Tappeiner HV. Ueber die Wirkung fluorescierenden stoffe auf Infusion-rien nach versuchen Von O. Raab. Munchener Medizinische Wochenschrift 1900;47:5.
53. Raab O. Ueber die wirkung fluorescierenden stoffe auf infusorien. Zeitschrift fur Biologie 1900;39:524-46.
54. Tappeiner HV, Jodlbauer A. Uber die wirkung der photodynamischen (fluorescierenden) stoffe auf protozoen und enzyme. Deutsches Archiv fur klinische Medizin 1904;80:327-487.
55. Tappeiner HV, Jodlbauer A. Die sensibilisierende wirkung fluoresci-erender substanzer. untersuchungen uber die photodynamische er-scheinung. FCW Vogel Leizig, 1907.
56. Scherer, H. Chemisch-physiologische untersuchungen. Annalen der Chemie und Pharmazie 1841;40:1-64.
57. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001;74:656-69.
58. Thudichum JL. Tenth report of the medical office of the privy council. London: HM Stationary Office, 1867.
59. Hausmann, W. Die sensibilisierende wirkung des hematoporphyrins. Biochemische Zeitschrift 1911;30:276-316.
60. Meyer-Betz, F. Untersuchungen uder die Biologische (photodynamische) wirkung des hamatoporphyrins und anderer derivative des blu- und galenfarbstoffs. Deutsches Archiv fur klinische Medizin 1913;112:476-503.
61. Winkelman J. The distribution of Tetraphenylporphinesulfonate in the tumor-bearing rat. Cancer Res 1962;22:589-96.
62. Daniell, M. D, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991;61:340-8.
63. Diamond I, Jaenicke R, Wilson CB, Mcdonagh AF, Nielsen S, Granelli SG. Photodynamic therapy of malignant tumors. Lancet 1972;2:1175-7.
64. Dougherty TJ, Gb Grindey, Fiel R, Weishaupt KR, Boyle DG. Photoradi-ation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975;55:115-21.
65. Kelly, JF, Snell, ME, Berenbaum,M. Photodynamic destruction of human bladder carcinomas. Brit J Cancer 1975;31:237-44.
66. Benhur E, Rosenthal I. Photosensitized inactivation of Chinese hamster cells by phthalocyanines. Photochem Photobiol 1985;42:129-33.
67. Phillips D. Chemical mechanisms in photodynamic therapy with phthalocyanines. Prog React Kinet 1997;22:175-300.
68. Wohrle D, Hirth A, Bogdahn-Rai T, Schnurpfeil G, Shopova M. Photo-dynamic therapy of cancer: second and third generations of photosensi-tizers. Russ Chem Bull 1998;47:807-16.
69. Sharman WM, Allen CM, Van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 1999;4:507-17.
70. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Sa-vard J, et al. Vascular targeted photodynamic therapy with Palladi-um-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treat-ment response. J Urol 2007;178:1974-9.
71. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular de-generation. Surv Ophthalmol 2000;45:195-214.
72. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascu-larization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Oph-thalmol 2001;119:198-207.
73. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, et al. Verteporfin therapy of subfoveal choroidal neo-vascularization in patients with age-related macular degeneration - Ad-ditional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002;120:1443-54.
74. Bressler NM. Verteporfin therapy for subfoveal choroidal neovasculari-zation in age-related macular degeneration - Three-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 5. Arch Ophthalmol 2002;120:1307-14.
75. Ferris F, Fine S, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
76. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004;3:436-50.
77. James WD. Acne. N Engl J Med 2005;352:1463-72.
78. Katsambas AD, Stefanaki C, Cunliffe WJ. Guidelines for treating acne. Clin Dermatol 2004;22:439-44.
79. Gold MH. Acne and PDT: new techniques with lasers and light sources. Lasers Med Sci 2007;22:67-72.
80. Ross EV. Optical treatments for acne. Dermatol Ther 2005;18:253-66.
81. Riddle CC, Terrell SN, Menser MB, Aires DJ, Schweiger ES. A review of photodynamic therapy (PDT) for the treatment of acne vulgaris. J Drugs Dermatol 2009;8:1010-9.
82. Hædersdal M, Togsverd-Bo K, Wulf HC. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad Dermatol 2008;22:267-78.
83. Nair CKK, Parida DK, Nomura T. Radioprotectors in radiotherapy. J Radiat Res 2001;42:21-37.
84. Das T, Chakraborty S, Sarma HD, Banerjee S. A novel [Pd-109] palla-dium labeled porphyrin for possible use in targeted radiotherapy. Radi-ochim Acta 2008;96:427-33.
85. Jia Z, Deng H, Pu M, Luo S. Rhenium-188 labelled me-so-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice. Eur J Nucl Med Mol Imaging 2008;35:734-42.
86. Vaum R, Heindel N, Burns H, Emrich J, Foster N. Synthesis and evalua-tion of an in-111-labeled porphyrin for lymph-node imaging. J Pharm Sci 1982;71:1223-6.
87. Crone-Escanye MC, Anghileri LJ, Robert J. In vivo distribution of 54Mn-hematoporphyrin derivative in tumor bearing mice. J Nucl Med Allied Sci 1988;32:237-41.
88. Hambright P, Fawwaz R, Valk P, McRae J, Bearden AJ. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice. Bioinorg Chem 1975;5:87-92.
89. Ali H, van Lier JE. Metal complexes as photo- and radiosensitizers. Chem Rev 1999;99:2379-450.
90. Policard A. Etude sur les aspects offerts par des tumeurs experimentales examinees a la lumiere de Wood. C R Soc Biol 1924;91:1423-8.
91. Korbler J. Untersuchung von krebsgewebe im fluoreszenzerregenden licht. Strahlentherapie 1931;41:510-8.
92. Auler H, Banzer G. Untersuchungen uber die rolle der porphyrine bei geschwulstkranken menschen und tieren. Zeitschrift fur Krebsforschung 1942;53:65-8.
93. Figge FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy: affinity of neoplastic, embryonic and traumatised tissues for porphyrins and metallo-porphyrins. Proc Soc Exp Biol Med 1948;68:640-1.
94. Manganiello LOJ, Figge FHJ. Cancer detection and therapy 11: Methods of preparation and biological effects of metallo-porphyrins. Bull Sch Med Univ Maryland 1951;36:3-7.
95. Rasmussen TDS, Ward GE, Figge FHJ. Fluorescenceof human lymphatic and cancer tissues following high doses of intravenous hematoporphy-rin. Cancer 1955;8:78-81.
96. Leblond F, Davis SC, Valdés PA, Pogue BW. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B 2010;98:77-94.
97. Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Met Based Drugs 2008;2008:276109.
98. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53:R61-R109.
99. Blake E, Allen J, Curnow A. An In vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX ac-cumulation for photodynamic therapy and/or fluorescence guided re-section. Photochem and Photobiol 2011;87:1419-26.
100. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluores-cence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000;93:1003-13.
101. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen H-J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
102. Pichlmeier U, Bink A, Schackert G, Stummer W. Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008;10:1025-34.
103. Valdés PA, Fan X, Ji S, Harris BT, Paulsen KD, Roberts DW. Estimation of brain deformation for volumetric image updating in protoporphyrin IX fluorescence-guided resection. Stereotact Funct Neurosurg 2010;88:1-10.
104. Valdés PA, Leblond F, Kim A, Harris BT, Wilson BC, Fan X, Tosteson TD, Hartov A, Ji S, Erkmen K, Simmons NE, Paulsen KD, et al. Quanti-tative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg 2011;115:11-7.
105. Bogaards A, Varma A, Collens SP, Lin A, Giles A, Yang VXD, Bilbao JM, Lilge LD, Muller PJ, Wilson BC. Increased brain tumor resection using fluorescence image guidance in a preclinical model. Laser Surg Med 2004;35:181-90.
106. Biesaga M, Pyrzyńska K, Trojanowicz M. Porphyrins in analytical chemistry. A review. Talanta 2000;51:209-24.
107. Beletskaya I, Tyurin VS, Tsivadze AY, Guilard R, Stern C. Supramolec-ular chemistry of metalloporphyrins. Chem Rev 2009;109:1659-713.
108. Hambright P. The coordination chemistry of metalloporphyrins. Coord Chem Rev 1971;6:247-68.
109. Wrenn FR, Myron L. Good, Handler P. The use of positron-emitting radioisotopes for the localization of brain tumors. Science 1951;113:525-7.
110. Sörensen J. How does the patient benefit from clinical PET? Theranostics 2012;2:427-36.
111. Yaghoubi SS. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics 2012;2:374-91.
112. Wilson B C, Firnau G, Jeeves WP, Brwon KL, Burns-McCormick DM. Chromatographic analysis and tissue distribution of radiocopper-lablled haematoporphyrin derivatives. Lasers Med Sci 1998;3:71-80.
113. Soucy-Faulkner A et al. Copper-64 labelled sulfophthalocyanines for positron emission tomography (PET) imaging in tumor-bearing rats. J Porphyrins Phthalocyanines 2008;12:49-53.
114. Bases R, Brodie SS, Rubenfeld S. Attempts at tumor localization using Cu 64-labeled copper porphyrins. Cancer 1958;11:259-63.
115. Firnau G, Wilson B C, Jeeves WP. 64Cu labelling of hematoporphyrin derivative for non-invasive in-vivo measurements of tumour uptake. Prog Clin Biol Res 1984;170:629-36.
116. Shi J, et al. Transforming a targeted porphyrin theranostic agent into a PET imaging probe for cancer. Theranostics 2011;1:363-70.
117. Iwai K, Kimura S, Ido T, Iwata R. Tumor uptake of [48V]Vanadyl-chlorine e6Na as a tumor-imaging agent in tumor-bearing mice. Nucl Med Biol 1990;17:775-80.
118. Lee D-E, Koo H, Sun I-C, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev 2012;41:2656-72.
119. Louie A. Multimodality imaging probes: design and challenges. Chem Rev 2010;110:3146-95.
120. Morgan CJ, Hendee WR. Introduction to magnetic resonance imaging. Denver: Multi-Media Publishing, 1984.
121. Braunschweiger PG, Schiffer LM, Furmanski P. 1H-NMR relaxation times and water compartmentalization in experimental tumor models. Magn Reson Imaging 1986;4:335-42.
122. Bottomley PA, Hardy CJ, Argersinger RE, Allen-Moore G. A review of 1H nuclear magnetic resonance relaxation in pathology: Are T1 and T2 diagnostic? Med Phys 1987;14:1-37.
123. Manabe Y, Longley C, Furmanski P. High-level conjugation of chelating agents onto immunoglobulins: use of an intermediary poly(L-lysine)-diethylenetriaminepentaacetic acid carrier. Biochim Bio-phys Acta 1986;883:460-7.
124. Chen C, Cohen JS, Myers CE, Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 1984;168:70-4.
125. Ni Y. Metalloporphyrins and functional analogues as MRI contrast agents. Curr Med Imag Rev 2008;4:96-112.
126. Ogan M, Revel D, Brasch R. Metalloporphyrin contrast enhancement of tumors in magnetic-resonance-imaging - a study of human carcinoma, lymphoma, and fibrosarcoma in mice. Invest Radiol 1987;22:822-8.
127. Furmanski P, Longley C. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. Cancer Res 1988;48:4604-10.
128. Young SW, Qing F, Harriman A, Sessler JL, Dow WC, Mody TD, Hemmi GW, Hao YP, Miller RA. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996;93:6610-5.
129. Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Bogaert J, Dymarkowski S, Yu J, Semmler W, Van de Werf F, Baert AL, Marchal G. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 2001;11:876-83.
130. Barkhausen J, Ebert W, Debatin JF, Weinmann HJ. Imaging of myocar-dial infarction: Comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol 2002;39:1392-8.
131. Ni Y, Marchal G, Jie Y, Lukito G, Petré C, Wevers M, Baert AL, Ebert W, Hilger C-S, Maier F-K, Semmler W. Localization of metalloporphy-rin-induced "specific" enhancement in experimental liver tumors: Comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol 1995;2:687-99.
132. Wilson BC, Jeeves WP, Lowe DM, Adam G. Light propagation in animal tissues in the wavelength range 375-825 nanometers. Prog Clin Biol Res 1984;170:115-32.
133. Zheng G, Chen J, Stefflova K, Jarvi M, Li H, Wilson BC. Photodynamic molecular beacon as an activatable photosensitizer based on prote-ase-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A 2007;104:8989-94.
134. Zheng G, Graham A, Shibata M, Missert JR, Oseroff AR, Dougherty TJ, Pandey RK. Synthesis of β-galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy. J Org Chem 2001;66:8709-16.
135. Lovell JF, Chan MW, Qi Q, Chen J, Zheng G. Porphyrin FRET acceptors for apoptosis induction and monitoring. J Am Chem Soc 2011;133:18580-2.
136. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nano-technology 2007;2:751-60.
137. Ali I, et al. Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets 2011;11:135-46.
138. Cohen EM, Ding H, Kessinger CW, Khemtong C, Gao J, Sumer BD. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells. Otolaryngol Head Neck Surg 2010;143:109-15.
139. Nishiyama N, Jang W-D, Kataoka K. Supramolecular nanocarriers inte-grated with dendrimers encapsulating photosensitizers for effective photodynamic therapy and photochemical gene delivery. New J Chem 2007;31:1074-82.
140. Ideta R, Tasaka F, Jang W-D, Nishiyama N, Zhang G-D, Harada A, Yanagi Y, Tamaki Y, Aida T, Kataoka K. Nanotechnology-based photo-dynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. Nano Lett 2005;5:2426-31.
141. Derycke ASL, de Witte PAM. Liposomes for photodynamic therapy. Adv Drug Delivery Rev 2004;56:17-30.
142. Jiang F, Lilge L, Grenier J, Li Y, Wilson MD, Chopp M. Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered photofrin. Laser Surg Med 1998;22:74-80.
143. Derycke ASL, Kamuhabwa A, Gijsens A, Roskams T, De Vos D, Kasran A, Huwyler J, Missiaen L, de Witte P a. M. Transferrin-conjugated lipo-some targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 2004;96:1620-30.
144. Gupta S, Chaudhury N, Muralidhar K, Dwarakanath B, Mishra A, Jain V. In vitro and in vivo targeted delivery of photosensitizers to the tumor cells for enhanced photodynamic effects. J Can Res Ther 2011;7:314-24.
145. Gijsens A, Missiaen L, Merlevede W, de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photo-dynamic activity. Cancer Res 2000;60:2197-202.
146. Morgan J, Lottman H, Abbou C, Chopin D. Comparison of direct and liposomal antibody conjugates of sulfonated Aluminum phthalocya-nines for selective photoimmunotherapy of human bladder-carcinoma. Photochem Photobiol 1994;60:486-96.
147. Shieh Y-A, Yang S-J, Wei M-F, Shieh M-J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 2010;4:1433-42.
148. Ricchelli F, Gobbo S, Jori G, Salet C, Moreno G. Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvi-ronment in lipid-membranes 2. The partition of hematoporphyrin and protoporphyrin in mitochondria. Eur J Biochem 1995;233:165-70.
149. Anderson VC, Thompson DH. Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid. Biochim Biophys Acta 1992;1109:33-42.
150. Lovell JF, Jin H, Ng KK, Zheng G. Programmed nanoparticle aggregation using molecular beacons. Angew Chem Int Ed 2010;49:7917-9.
151. Lovell JF, Jin CS, Huynh E, MacDonald TD, Cao W, Zheng G. Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew Chem Int Ed 2012;51:2429-33.